Stay updated with breaking news from Diagnostics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cantor Fitzgerald restated their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $4.00 price target on the stock. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2023 earnings at ($1.14) EPS and FY2024 earnings at ($0.82) EPS. Separately, […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Equities researchers at Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Lucid Diagnostics in a research report issued on Thursday, August 17th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($1.14) for the year, up from their […]
/PRNewswire/ -- The "Syndromic Multiplex Diagnostic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)" report has been added to...
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of...
SALT LAKE CITY, Aug. 18, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic